Targeted therapies like epidermal growth factor receptor (EGFR) inhibitors, used in metastatic CRC, can cause electrolyte disturbances, particularly hypomagnesemia, which can prolong QT interval and increase the risk of fatal arrhythmias and sudden cardiac death [10]. This evidence concerns the gene EGFR and colorectal carcinoma.